550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors

Abstract

Growth Differentiation Factor 15 (GDF15) has been shown to have both protumorigenic and procachectic effects. NGM120 is a novel, 1st-in class, humanized monoclonal antibody that inhibits GFRAL (the receptor for GDF15) resulting both in antitumor and anticachexia effects in experimental models. In a healthy volunteer study, NGM120 (10-400 mg) was well tolerated with a favorable safety profile. We present the data from Ph1a/1b dose finding study (NCT04068896) of NGM120 and NGM120 + gemcitabine (Gem)/nab-paclitaxel (nab-P) in advanced cancer pts.